In April 2021, Fitbit announced a trial to determine whether its smartwatches can accurately detect hypertension. Preliminary research suggests the device can be used to measure blood pressure from the wrist, but the new study will extend those findings to a larger population. The company acknowledges that although there is great interest in monitoring blood pressure using wearables, this method has not yet been properly validated. Wrist measurements have so far failed to prove as accurate as those from a cuff. Fitbit users in the US who are at least 20 years old are participating in the study.

After working to make its continuous glucose monitoring systems compatible with the major players in the diabetes device industry, Dexcom is opening its doors much wider. With an FDA blessing for Dexcom’s new web-based APIs, the company can invite digital health companies to feed its CGM data into their own health apps and devices—potentially expanding the different ways people with diabetes can share and use their blood sugar stats.

Accidental medical errors, specifically related to drug delivery and toxicity-related events, are the third largest cause of death among Americans, according to CNBC. More than 131 million adult Americans are making some sort of prescription medication in the form of an ingestible. Over 11.8 million people worldwide use an injectable device to deliver their medication daily. Now, the two devices that were mentioned, ingestible pills and the syringe needle used to inject medication, were invented in 1500 BCE and 1853 respectively. These forms of pharmacology delivery have not had dramatic changes since their inception into the world of medication. Even when taking into consideration medical safety, the largest changes in the form that these devices take have come from the inversion of the needle following injection and the “controlled-release” of medication from the pill form.

As per the permission granted by the Federal Communications Commission (FCC), Amazon's Radar sensor will operate in the 57-64GHz frequency band. The spectrum had previously been used for facilitating secure communications but since 2001 has been set aside by the FCC for unlicensed wireless communications.

Addressing the need for streamlined power management solutions for energy harvesting hardware, e-peas has unveiled a new family of battery charger devices. While the company’s existing power management ICs (PMICs) offer direct power delivery to the application, as well as the charging of energy storage elements (such as Li-Ion batteries or super-capacitors), the AEM10900, AEM10300 and AEM30300 are fully dedicated to the charging function. This allows them to be employed in situations that need a simpler implementation, where there are space or cost constraints that need to be considered.

Medical Wearables is a fast growing market segment that requires Boyd’s unique expertise in developing smaller, lighter, higher performing solutions for next generation applications. The article highlights how to best utilize these technologies to reduce weight and landed costs, as well as streamline the supply chain for the full spectrum of Medical Devices.

This wearable hybrid device, functioning as both a biofuel cell and a supercapacitor, is demonstrated to deliver high-power pulses and be rapidly self-recharged using enzymatic oxidation of lactate biofuel from human perspiration. This work enabled material-level integration of both functionalities on the same set of electrodes, thus reducing the system complexity and minimizing the device footprint.

The new skin is equipped with artificial sweat ducts that resemble pores in human skin and that have been etched through the material’s ultrathin layers. This ensures that sweat can escape through the electronic skin avoiding damaging and deteriorating the wearable skin.

Medical wearables provide practitioners with a treasure trove of health data that can be used to monitor and treat patients – and they are only getting better

We’re used to the idea of wearable technology measuring everything from our temperature and heart rate, to blood glucose levels and sleep. But what if we moved those devices inside the body? That’s what Swedish startup DSRuptive does, using small glass capsules — the size of a grain of rice.
On Wednesday, the company announced the results of the first clinical study showing the effectiveness of injectable implants in monitoring body temperature.
The results are a glimpse into a future when implants could be the norm for everything, from health monitoring to payments and identification.

We demonstrated a valuable supplement to traditional PROs by using smartphone-based activity data. This methodology yields a rich data set that has the potential to augment our understanding of patient recovery.

NeoRhythm was developed by MDCN technology Inc. It’s a neurostimulation headband that will help you to de-stress, focus, sleep & meditate better, and more. The headband uses a safe magnetic method of neuromodulation to target specific areas of the brain with the purpose of helping the user reach a desired state of mind such as relaxation, focus, or sleep.

Sleep apnea is a common sleep disorder in which breathing starts and stops. According to a 2018 study from ResMed, the disorder affects over 936 million people around the world. Men are more likely to have sleep apnea than women. Weight and age can also play a factor in the illness as can smoking and alcohol use.
According to Grand View Research, the global sleep apnea devices market was valued at $3.7 billion last year, and the market is only supposed to get larger. Grand View estimates that the market will expand at a compound annual growth rate of over 6% over the next six years.

It’s stretchable, like a band-aid, waterproof, and long lasting. In today’s Medical Moment, how this small patch may soon take the place of invasive health monitors. For many diabetics, daily monitoring of blood sugar means a finger prick. But what if there was a better way?

The FDA recommends patients keep any consumer electronic devices that may create magnetic interference, including cell phones and smart watches, at least six inches away from implanted medical devices, in particular cardiac defibrillators. Many implanted medical devices have FDA-approved information written for patients (patient labeling), which cautions patients to keep all cell phones and smart watches at least six inches from the implanted medical device.

Silk fibroin has been widely used as fundamental components for the construction of biocompatible flexible electronics, particularly for wearable and implantable devices. Furthermore, in recent years, more attention has been paid to the investigation of the functional characteristics of silk fibroin, such as the dielectric properties, piezoelectric properties, strong ability to lose electrons, and sensitivity to environmental variables. Here, this paper not only reviews the preparation technologies for various forms of silk fibroin and the recent progress in the use of silk fibroin as a fundamental material but also focuses on the recent advanced works in which silk fibroin serves as functional components. Additionally, the challenges and future development of silk fibroin-based flexible electronics are summarized.

Taking medication on a schedule is essential to ensuring proper dosage and treatment but can be difficult to accommodate, so the 'Tapp' medication packaging has been developed to streamline the process. Designed by Cambridge Consultants, the electronic strip works by being attached onto blister packs and connecting to a smartphone thanks to near-field communication (NFC) technology. Users can then utilize the accompanying app to set up reminders, input specific information about the medication and much more.

SmartPilot for YpsoMate enables advanced adherence monitoring by transforming the proven YpsoMate autoinjector into a fully connected smart product system. It supports the seamless provision of therapy-relevant data to patients, physicians, and other healthcare stakeholders. In so doing, it takes up both market and technology needs to adopt smart devices to improve therapy outcomes.

For most people, a similar immune response gets instigated during a SARS-CoV-2 (coronavirus). However, in covid patients who become seriously ill, antibody production is derailed. These patients not only produce a lot of antibodies but also antibodies with deviant structures. This creates an extreme inflammatory response in their lungs. Menno de Winter, an expert in the field of immune cells, adds that the antibodies produced in our body are Y-shaped. The upper part of these antibodies binds to the virus, while the lower part binds with immune cells in our lungs and activates them.

Schreiner MediPharm designed the label with an integrated NFC chip precisely for the combination of the UnoPen and the SmartPilot. With the NFC-Label, the drug can automatically be identified, authenticated and checked in terms of its expiration date. Via the smart device, the injection’s time, date and dosage are tracked and transmitted to the patient’s related smartphone app via Bluetooth. Patients are interactively guided through the injection process, assisted in correctly using the pen in real time, and informed about inconsistencies such as deviations from the therapy plan or accidental attempts to inject themselves twice.

When incorporated with a low-power temperature sensor to transform the chip into a real-time temperature probe, the device possesses the ability to monitor body temperature in addition to small variations in temperature linked to the therapeutic use of ultrasound. In the study, the implant's proof-of-concept was carried out on live mice, in which it employed ultrasound neurostimulation. This involved implanting up to seven mice at once with intramuscular injection via syringe.

Glooko, a provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions, has announced a strategic collaboration with Eli Lilly and Company for people with diabetes that use Lilly’s connected insulin pen solutions.

Renovia, a digital health startup that developed an app-based program for urinary incontinence, raised $17 million in funding. The company recently completed a clinical trial that it plans to share with insurance carriers as evidence of its efficacy.

Implandata Ophthalmic Products, a digital health company, has received Breakthrough Device Designation (BDD) from the Food and Drug Administration (FDA) for its Eyemate system for digitally enabled remote patient monitoring and management of glaucoma.

IMC sets new clinical research standard with CertiScan® 2.0 end-to-end medication adherence analytics, disrupting smart device marketplace with customer-friendly ROI-driven data plans

Medical device manufacturers should take advantage of valuable market opportunities by updating legacy devices. Augmenting an existing medical device can extend the life of your product and it can be accomplished by connecting to a gateway module equipped with wifi, Bluetooth, and cell connectivity. This will enable the device to connect to a mobile device such as a smartphone or tablet and provide customers with a modern user interface, cloud connectivity, and a plethora of other advantages. Here we will explore important questions associated with expanding connectivity to an existing medical device.

Fitbit is launching a trial to see if its its newest smartwatch could use pulse arrival time to measure blood pressure. Other wearable companies have tried to add wrist-based blood pressure features to their devices, but so far, they have limited accuracy.